ChiCTR‐TRC‐08000267.

Study name	The role of LMWH combined with TACE in hepatocellular carcinoma
Methods	Randomised parallel controlled trial Phase: postmarket
Participants	Adults with hepatocellular carcinoma that is not amenable to surgical resection, liver transplantation, or local ablative therapy; without metastasis out of liver
Interventions	Intervention: hypodermic injection LMWH 4100 IU each 12 hours in 6 weeks Control: no intervention
Outcomes	Primary outcomes: survival time; survival time with no tumour progression Secondary outcome: response rate
Starting date	1 December 2008
Contact information	Jiamei Yang, yang‐jia‐mei@163.com
Notes	Recruitment status: completed Primary sponsor: Shanghai Eastern Hepatobiliary Surgery Hospital